News
1d
Zacks Investment Research on MSNNovo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on ItNovo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...
16h
TipRanks on MSNNovo Nordisk’s Stock Soars Amid Strategic MovesNovo Nordisk ( ($NVO) ) has risen by 10.44%. Read on to learn why. Novo Nordisk has seen a notable 10.44% increase in its stock price over the ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Explore more
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and ...
Novo Nordisk Pakistan hosted “Unordinary Partnerships to Shape a Healthier Tomorrow” that brought together healthcare ...
Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results